Comparative Effects of CGF and PRP in Impacted Third Molar Surgery

NCT ID: NCT07320170

Last Updated: 2026-01-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-02
• Study Completion Date: 2025-05-02

Brief Summary

This study evaluates the effects of two different blood products obtained from the patient's own blood (Concentrated Growth Factor [CGF] and Platelet-Rich Plasma [PRP]) on healing after wisdom tooth extraction. The aim is to determine whether applying these materials to the extraction area reduces postoperative pain, facial swelling, and the risk of dry socket compared to standard healing.

Detailed Description

This prospective, randomized, controlled clinical trial compares the efficacy of autologous platelet concentrates in reducing postoperative sequelae following the surgical extraction of impacted mandibular third molars.

A total of 42 patients were randomly assigned to one of three groups:

Control Group: Standard surgical extraction without additional biomaterials.

CGF Group: Standard extraction followed by the placement of a CGF clot into the extraction socket.

PRP Group: Standard extraction followed by submucosal injection of PRP.

The primary outcome measured is postoperative pain (Visual Analog Scale) on postoperative days 1, 3, and 7. The secondary outcomes include facial swelling (linear measurements) on postoperative days 1, 3, and 7, and the incidence of alveolar osteitis (dry socket).

Conditions

Impacted Third Molar

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Control Group

Standard surgical extraction was performed without the application of any additional biomaterials.

Group Type: NO_INTERVENTION

No interventions assigned to this group

CGF Group

Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket.

Group Type: EXPERIMENTAL

Concentrated Growth Factor (CGF)

Intervention Type: BIOLOGICAL

Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket immediately after tooth removal.

PRP Group

Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP).

Group Type: EXPERIMENTAL

Platelet-Rich Plasma (PRP)

Intervention Type: BIOLOGICAL

Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP) around the extraction site.

Interventions

Concentrated Growth Factor (CGF)

Standard surgical extraction followed by the placement of a Concentrated Growth Factor (CGF) clot into the extraction socket immediately after tooth removal.

Intervention Type: BIOLOGICAL

Platelet-Rich Plasma (PRP)

Standard surgical extraction followed by submucosal injection of Platelet-Rich Plasma (PRP) around the extraction site.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Patients aged between 18 and 50 years.
• Systemically healthy individuals classified as American Society of Anesthesiologists (ASA) Class I or Class II.
• Presence of impacted mandibular third molars (teeth 38 and 48 according to Fédération Dentaire Internationale (FDI) notation).
• Mesioangular impaction with bone retention according to Winter's classification.
• Class II relationship to the ramus according to the Pell and Gregory classification.
• Level B or Level C depth of impaction according to the Pell and Gregory classification.

Exclusion Criteria

• Patients younger than 18 years.
• Habitual smoking or alcohol consumption.
• Presence of coagulation (bleeding) disorders.
• Systemic diseases affecting wound healing or use of medications that compromise healing.
• Pregnancy or lactation.
• Presence of active pericoronitis associated with the tooth.
• Presence of pathological lesions (cysts or tumors) associated with the impacted tooth.
• Uncontrolled periodontal disease in the oral cavity.
• Known allergy to any medications used in the study protocol.
• Inability to comply with follow-up visits.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Recep Tayyip Erdogan University

OTHER

Sponsor Role: lead

Responsible Party

Emin Valiyev

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Recep Tayyip Erdogan University, Faculty of Dentistry

Rize, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

2024/52

Identifier Type: -

Identifier Source: org_study_id